Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure

This study has been completed.

Sponsored by:	Novartis
Information provided by:	Novartis
ClinicalTrials.gov Identifier:	NCT00219180

Purpose

To evaluate the efficacy and safety of aliskiren alone and in combination with valsartan given to patients with essential hypertension

Condition	Intervention	Phase
Hypertension	Drug: aliskiren	Phase III

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Valsartan Aliskiren

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment
Official Title:	An 8-Week Multi-Center, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren (150 mg and 300 mg) Administered Alone and in Combination With Valsartan (160 mg and 320 mg) in Patients With Hypertension

Further study details as provided by Novartis:

Primary Outcome Measures:

Secondary Outcome Measures:

Change from baseline in systolic blood pressure after week 8
Diastolic blood pressure < 90 mmHg or a reduction of > 10 mmHg after 4 and 8 weeks
Blood pressure control target of < 140/90 mmHg after 4 and 8 weeks
Evaluate 24-hour ambulatory blood pressure monitoring in a subset of patients

Estimated Enrollment:	1784
Study Start Date:	June 2005

Eligibility

Criteria

Inclusion Criteria

Exclusion Criteria

Other protocol-defined exclusion criteria may apply.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00219180

Locations

United States, New Jersey
Novartis Pharmaceuticals
East Hanover, New Jersey, United States, 07936
Germany

Investigative Centers, Germany

Sponsors and Collaborators

Novartis

Investigators

Study Director:

Novartis Pharmaceuticals

More Information

Publications indexed to this study:

Study ID Numbers:	CSPP100A2327
Study First Received:	September 12, 2005
Last Updated:	November 13, 2006
ClinicalTrials.gov Identifier:	NCT00219180
Health Authority:	United States: Food and Drug Administration

Keywords provided by Novartis:

Hypertension, Aliskiren

Study placed in the following topic categories:

Vascular Diseases
Valsartan
Hypertension

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 15, 2009